Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy

Abstract

Background: This analysis assesses the efficacy and safety of a modified FOLFOX (oxaliplatin/leucovorin [LV]/ 5-fluorouracil [5-FU]) regimen given with a low dose of LV. Patients and Methods: Forty patients with previously untreated metastatic colorectal cancer were enrolled to receive every-2-week cycles of oxaliplatin 100 mg/m2 intravenously administered over 2 hours concurrently with LV 20 mg/m2 bolus and 5-FU 400 mg/m2 bolus, followed by a 46-hour infusion of 5-FU 2.4 g/m2. Results: Thirty-nine patients received ≥ 1 oxaliplatin dose and a median of 10 treatment cycles (range, 1-13 cycles). Thirteen patients (34%) experienced grade 3/4 neutropenia, whereas 21% of patients experienced grad..